Sangamo Therapeutics Azioni (NASDAQ: SGMO)

Sangamo Therapeutics

SANGAMO THERAPEUTICS INC

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NMTC

SGMO

Movimenti di mercato: cosa attendersi da queste società dopo gli ultimi annunci e risultati finanziari, con reazioni contrastanti.

Guess?, Simulations Plus e altre 3 azioni da tenere d&#39;occhio oggi

GETY

STNE

Analisi e previsioni: ecco i titoli che potrebbero superare le aspettative degli analisti, generando guadagni interessanti.

Il martedì di Wall Street: 5 azioni pronte a sorprendere il mercato

AMBO

CETX

CMPO

Le principali azioni da tenere d&#39;occhio nel mercato pre-apertura, con analisi delle performance recenti e delle prospettive future.

Pre-market: 5 titoli da monitorare oggi, 31 dicembre 2024

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

Press Releases

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Biotech

General

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

C4 Therapeutics

Caribou Biosciences

Cardiff Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Elicio Therapeutics

enGene Holdings

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Lexeo Therapeutics

MEI Pharma

Nkarta

Nuvectis Pharma

RAPT Therapeutics

AVITA Medical

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Instil Bio

TriSalus Life Sciences, Inc. - Common Stock

Comments

Sangamo Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO